Study guide

13.6 Hypocalcaemia & Metabolic Bone Disease

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

13.6 Hypocalcaemia & Metabolic Bone Disease

Key Takeaways Explain This Topic AI

Hypomagnesaemia impairs PTH secretion and action, so hypocalcaemia will not correct until magnesium is replaced.

Osteoporosis has normal calcium, phosphate and alkaline phosphatase; osteomalacia shows low or normal calcium with low phosphate and raised alkaline phosphatase.

Paget's disease of bone shows an isolated raised alkaline phosphatase with normal calcium and phosphate, and is treated with bisphosphonates when symptomatic.

Last updated: September 2026

  • 3. Hypocalcaemia & Magnesium-Dependent PTH Resistance
  • Clinical Manifestations of Neuromuscular Irritability

Hypocalcaemia lowers the threshold potential of peripheral excitable membranes, producing spontaneous depolarization:

Symptoms: Perioral and digital tingling/paresthesias, muscle cramps, carpopedal spasm, stridor (laryngospasm), and generalized seizures.

Physical Examination Signs:

Chvostek's Sign: Light tapping over the facial nerve trunk anterior to the external auditory meatus elicits ipsilateral twitching of facial muscles (orbicularis oris, corner of mouth, or nose).

Trousseau's Sign: Inflation of a sphygmomanometer blood pressure cuff to 20 mmHg 20\text{ mmHg} 20 mmHg above systolic blood pressure for 3 minutes precipitates painful carpopedal spasm ( flexion of the wrist and metacarpophalangeal joints, extension of the interphalangeal joints, and adduction of the thumb ; 'main d'accoucheur'). Trousseau's sign is significantly more sensitive ( 94 % 94\% 94% ) and specific ( 99 % 99\% 99% ) than Chvostek's sign.

Electrocardiogram: Prolongation of the ST segment and corrected QT interval (QTc) , predisposing to Torsades de Pointes and ventricular arrhythmias.

Etiologies of Hypocalcaemia

Post-Surgical Hypoparathyroidism: Accidental excision or devascularization of parathyroid glands during total thyroidectomy, completion thyroidectomy, or radical neck dissection. Symptoms classically manifest 24 to 48 hours post-operatively.

Autoimmune Hypoparathyroidism: Isolated or component of Autoimmune Polyendocrine Syndrome Type 1 (APS-1).

Severe Vitamin D Deficiency: Nutritional deficiency, malabsorption (coeliac disease, gastrectomy, bariatric surgery), or end-stage renal disease ( C Y P 27 B 1 CYP27B1 C Y P 27 B 1 deficiency).

Acute Pancreatitis: Extravasated pancreatic lipases hydrolyze retroperitoneal fat into free fatty acids, which chelate calcium ions to form insoluble calcium salts ( fat saponification ).

Severe Hypomagnesaemia ( < 0.5 mmol/L < 0.5\text{ mmol/L} < 0.5 mmol/L ): (CRITICAL EXAM PEARL): Magnesium is an obligate intracellular cofactor for adenylate cyclase and G-protein coupled receptor signalling. Severe hypomagnesaemia (caused by chronic alcohol misuse, proton pump inhibitors, loop diuretics, or malabsorption) causes both impaired parathyroid hormone secretion AND severe end-organ skeletal/renal resistance to circulating PTH . The resulting hypocalcaemia is completely refractory to intravenous calcium administration until serum magnesium is replenished .

Acute Management of Severe Hypocalcaemia

Severe or symptomatic hypocalcaemia (corrected calcium < 1.90 mmol/L < 1.90\text{ mmol/L} < 1.90 mmol/L ) requires immediate emergency intervention:

Administer intravenous calcium gluconate 10% (10 mL in 50–100 mL of 5% dextrose infused over 10–20 minutes) with continuous ECG monitoring. Calcium gluconate is preferred over calcium chloride due to a substantially lower risk of severe tissue necrosis if extravasation occurs.

Follow with a continuous maintenance intravenous calcium infusion.

Concomitantly replenish serum magnesium with intravenous magnesium sulphate (e.g. 4 g 4\text{ g} 4 g in 100 mL 100\text{ mL} 100 mL 0.9 % 0.9\% 0.9% saline over 30 minutes).

4. Metabolic Bone Disease

Metabolic bone disorders alter bone remodeling and mineral homeostasis through distinct pathophysiological pathways:

Condition Corrected Calcium Serum Phosphate Alkaline Phosphatase (ALP) Parathyroid Hormone (PTH) Hallmark Diagnostic Findings

Normal Reference 2.20 – 2.60 mmol/L 2.20\text{–}2.60\text{ mmol/L} 2.20 – 2.60 mmol/L 0.8 – 1.4 mmol/L 0.8\text{–}1.4\text{ mmol/L} 0.8 – 1.4 mmol/L 30 – 130 IU/L 30\text{–}130\text{ IU/L} 30 – 130 IU/L 1.6 – 6.9 pmol/L 1.6\text{–}6.9\text{ pmol/L} 1.6 – 6.9 pmol/L Normal skeletal architecture

Osteoporosis Normal Normal Normal Normal DEXA T-score ≤ − 2.5 \le -2.5 ≤ − 2.5 ; normal mineral:matrix ratio

Osteomalacia / Rickets Low or Normal Low Elevated Elevated (Secondary) Looser's zones (pseudofractures); defective osteoid mineralization; low 25 -OH-D 25\text{-OH-D} 25 -OH-D

Paget's Disease of Bone Normal Normal Markedly Elevated Normal Disorganized bone remodeling; 'cotton-wool' skull; sabre tibia; mosaic histology

Primary Hyperparathyroidism Elevated Low or Normal Normal or Elevated Elevated / Inappropriate Subperiosteal cortical resorption; nephrolithiasis; high urinary calcium

Renal Osteodystrophy (CKD) Low or Normal Elevated Elevated Markedly Elevated (Secondary) Impaired phosphate clearance and loss of renal 1 α 1\alpha 1 α -hydroxylase

Osteoporosis

Pathophysiology: Characterized by low bone mineral density and microarchitectural deterioration of bone tissue, leading to increased bone fragility. The mineral-to-collagen matrix ratio remains entirely normal (unlike osteomalacia).

Diagnosis: Dual-energy X-ray absorptiometry (DEXA) scanning of the lumbar spine and femoral neck:

T-Score (compared to young healthy sex-matched reference peak bone mass):

  • Normal: T-score ≥ − 1.0 \text{T-score} \ge -1.0 T-score ≥ − 1.0
  • Osteopenia: − 1.0 > T-score > − 2.5 -1.0 > \text{T-score} > -2.5 − 1.0 > T-score > − 2.5
  • Osteoporosis: T-score ≤ − 2.5 \text{T-score} \le -2.5 T-score ≤ − 2.5

Severe (Established) Osteoporosis: T-score ≤ − 2.5 \text{T-score} \le -2.5 T-score ≤ − 2.5 in the presence of one or more documented fragility fractures

Z-Score: Compared to age- and sex-matched peers. A Z -score ≤ − 2.0 Z\text{-score} \le -2.0 Z -score ≤ − 2.0 suggests secondary causes (hypogonadism, hypercortisolism, coeliac disease, hyperthyroidism, myeloma).

Fracture Risk Assessment: FRAX tool and NOGG (National Osteoporosis Guideline Group) intervention thresholds.

Pharmacotherapy:

Oral Bisphosphonates (First-Line): Alendronic acid ( 70 mg 70\text{ mg} 70 mg once weekly) or Risedronate ( 35 mg 35\text{ mg} 35 mg weekly). Inhibit osteoclastic farnesyl pyrophosphate synthase, inducing osteoclast apoptosis.

Mandatory Administration Instructions: Swallow whole with a full glass of plain tap water, upon waking in the morning, on an empty stomach at least 30 minutes before any food, beverage, or other medications, and remain sitting or standing upright for at least 30 minutes to prevent chemical pill-induced oesophagitis and ulceration.

Rare Long-Term Complications: Osteonecrosis of the jaw (ONJ) (mandates pre-treatment dental review) and atypical femoral fractures (transverse subtrochanteric/diaphyseal fractures, often preceded by dull thigh or groin pain). Prompts consideration of a 'bisphosphonate holiday' after 5 years of oral or 3 years of IV therapy in lower-risk patients.

Intravenous Bisphosphonates: Zoledronic acid ( 5 mg 5\text{ mg} 5 mg IV infusion once yearly) . Preferred for upper gastrointestinal intolerance, malabsorption, or poor oral compliance.

Denosumab: Fully human monoclonal antibody directed against RANKL , preventing osteoclast formation and survival. Administered 60 mg 60\text{ mg} 60 mg subcutaneously every 6 months. Critical Caveat: Discontinuation causes a rapid rebound surge in bone resorption and a high risk of multiple vertebral fractures; treatment must never be stopped without transitioning to a bisphosphonate.

Teriparatide: Recombinant human PTH 1–34 administered daily subcutaneously for up to 24 months. Potent anabolic agent stimulating osteoblastic bone formation. Contraindicated in patients with prior skeletal irradiation, bone metastases, or Paget's disease due to theoretical osteosarcoma risk.

Osteomalacia & Rickets

Pathophysiology: Defective mineralization of newly synthesized organic bone matrix (osteoid) in adults (osteomalacia) or unclosed epiphyseal growth plates in children (rickets). Most commonly caused by severe vitamin D deficiency (serum 25 -hydroxyvitamin D < 25 nmol/L 25\text{-hydroxyvitamin D} < 25\text{ nmol/L} 25 -hydroxyvitamin D < 25 nmol/L ) or chronic phosphate wasting.

Clinical Presentation: Widespread diffuse, dull, aching bone pain and tenderness (particularly over the sternum, pelvis, and anterior tibiae), accompanied by severe proximal myopathy resulting in a characteristic waddling gait and difficulty rising from chairs.

Radiological Signatures: Generalized osteopenia with pathognomonic Looser's zones (pseudofractures) : narrow, transverse, radiolucent bands perpendicular to the cortex with sclerotic margins, representing unmineralized osteoid stress fractures. Classically located on the medial femoral neck, pubic rami, ribs, and lateral borders of the scapula.

Biochemical Profile: Low or low-normal corrected calcium, low serum phosphate, elevated alkaline phosphatase (ALP) , markedly suppressed 25 -hydroxyvitamin D 25\text{-hydroxyvitamin D} 25 -hydroxyvitamin D , and secondary hyperparathyroidism ( elevated PTH ).

Paget's Disease of Bone (Osteitis Deformans)

Pathophysiology: Focal disorder of accelerated, disorganized bone remodeling initiated by hyperactive, giant multinucleated osteoclasts (frequently associated with mutations in the sequestosome 1 gene, SQSTM1 / p62 ). Subsequent frenzied osteoblastic bone formation yields chaotic, poorly mineralized woven bone with a characteristic 'mosaic' or 'jigsaw' architectural pattern of irregular cement lines under polarized light microscopy.

Epidemiology & Presentation: Typically presents in individuals > 55 > 55 > 55 years of age (highest prevalence in the UK, particularly Lancashire). Often discovered incidentally on routine blood tests showing an isolated, markedly elevated serum alkaline phosphatase (ALP) with completely normal serum calcium and phosphate .

Clinical Signs & Complications:

Localized constant bone pain and skeletal deformities: increasing hat size (cranial vault expansion), frontal bossing, anterior bowing of the tibia ( sabre tibia ), and enlarged warm bones due to marked cutaneous hypervascularity.

Cranial Nerve Compression: Bony encroachment of the internal auditory meatus or temporal bone petrous remodeling leads to sensorineural hearing loss / deafness (CN VIII) in up to 30 % 30\% 30% .

High-Output Cardiac Failure: Extensive pagetic bone hypervascularity functions as multiple microscopic arteriovenous shunts.

Malignant Transformation: Development of secondary osteosarcoma occurs in < 1 % < 1\% < 1% of patients; suspected if there is a sudden, dramatic intensification of localized bone pain, new soft tissue mass, or rapid surge in ALP.

Radiology: Sclerotic and lytic phases: osteolytic wedge ('blade-of-grass' or 'candle-flame' sign), thickened trabeculae, cortical expansion, and cotton-wool appearance of the calvarium.

Treatment: Indicated for bone pain localized to pagetic sites, or involvement of high-risk locations (skull base, weight-bearing joints, vertebrae). The treatment of choice is intravenous Zoledronic acid (5 mg single infusion) , which rapidly normalizes alkaline phosphatase and induces durable remission lasting years.